$36.05
-0.39-1.07%
At close: Aug 31, 5:00 PM EST
$36.90
0.852.36%
After Hours: 4:32 PM EST
Teva Pharmaceutical Industries Ltd
TEVANYSE
Teva Pharmaceutical Indus Earnings & Forecasts
Teva Pharmaceutical Indus (TEVA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Teva Pharmaceutical Indus Guidance
Teva Pharmaceutical Indus (TEVA) last issued guidance on July 29, 2026 for fiscal year 2026. The company guided earnings per share in the range of $1.91 - $2.11, compared to a consensus EPS estimate of $2.17. Teva Pharmaceutical Indus also guided revenue in the range of $16.5B - $16.85B for the period.
Compared to prior guidance, Teva Pharmaceutical Indus lowered its EPS outlook from a previous range of $2.57 - $2.77. On the revenue side, the company maintained its revenue forecast from a prior range of $16.4B - $16.8B.
Teva Pharmaceutical Indus has issued 19 guidance updates between November 3, 2022 and July 29, 2026. During this period, the company raised its outlook 6 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.41 | $0.46 | $0.63 | $0.67 |
| Actual | $0.02 | $0.53 | $0.96 | $0.78 |
| Surprise | -95.1% | +15.2% | +52.4% | +16.4% |
| Revenue | ||||
| Estimate | $4.07B | $3.81B | $4.33B | $4.34B |
| Actual | $4.14B | $3.98B | $4.71B | $4.48B |
| Surprise | +1.82% | +4.41% | +8.77% | +3.20% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.71 | $0.74 | $0.62 | $0.71 |
| Revenue | ||||
| Consensus | $4.24B | $4.24B | — | — |
